Bleeding in Patients Undergoing Percutaneous Coronary Interventions: A Risk Model From 302,152 Patients in the NCDR. Sameer K. Mehta MD, Andrew D. Frutkin.

Slides:



Advertisements
Similar presentations
What Have We Learned from the CRUSADE Registry
Advertisements

Sumeet Subherwal, Richard G. Bach, Anita Y. Chen, Brian F. Gage, Sunil V. Rao, Tracy Y. Wang, W. Brian Gibler, E. Magnus Ohman, Matthew T. Roe, Eric D.
Impact of Anemia on One-Year Ischemic Events and Mortality Among Patients with Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention Steven.
STS 2015 John V. Conte, MD Professor of Surgery Johns Hopkins University School of Medicine On Behalf of the CoreValve US Investigators Transcatheter Aortic.
Impact of Anticoagulant and Anti-platelet Therapy on ICD Implant-Related Bleeding and Thromboembolic Events in Patients Enrolled in the NCDR ® ICD Registry.
Comparison of the New Mayo Clinic Risk Scores and Clinical SYNTAX Score in Predicting Adverse Cardiovascular Outcomes following Percutaneous Coronary Intervention.
Radial versus Femoral Randomized Investigation in ST Elevation Acute Coronary Syndrome the RIFLE STEACS study Enrico Romagnoli, MD PhD Principal investigators:
Long-term Outcomes of Patients with ACS and Chronic Renal Insufficiency Undergoing PCI and being treated with Bivalirudin vs UFH/Enoxaparin plus a GP IIb/IIIa.
The Radial Approach to Percutaneous Coronary Intervention Is Associated With a Lower Risk for Complications Regardless of Radial Procedure Volume: A Report.
Predictors of Major Vascular Access Site Complications in Patients with Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: Insights.
CPORT- E Trial Randomized trial comparing medical, economic and quality of life outcomes of non-primary PCI at hospitals with and without on-site cardiac.
TOTAL Stroke in the TOTAL trial: Randomized trial of manual aspiration Thrombectomy in STEMI TOTAL Trial Investigators.
Martial Hamon 1, Steven Marso 2, Sunil Rao 3, Marco Valgimigli 4, Freek Verheugt 5, Anthony Gershlick 6, Yamei Wang 8, Gabriel Steg 7, Efthymios Deliargyris.
Factors influencing treatment decisions for coronary artery disease after cardiac catheterization American Heart Association November 18, 2013 Dallas,
WG Hellenic PCI Registry Organization - Structure - Directions - Initial Recordings Georgios I. Papaioannou, MD,
Validation of Mayo Clinic Risk Adjustment Model for In-Hospital Mortality following Percutaneous Coronary Interventions using the National Cardiovascular.
1 1 The Use of Percutaneous Coronary Intervention in Patients with Class I Indications for Coronary Artery Bypass Graft Surgery: Data from the National.
Patterns of red blood cell transfusion use and outcomes in patients undergoing percutaneous coronary intervention in contemporary clinical practice: Insights.
Hamon M 1, Nienaber C 2, Galli S 3, Huber K 4, Gulba D 5, Hill J 6, Lafont A 7, Cequier A 8, Bernstein D 9, Deliargyris E 9 Institutions: 1. Centre Hospitalier.
Author Disclosures Differences in Implantation-Related Adverse Events Between Men and Women Receiving ICD Therapy for Primary Prevention Differences in.
1 Incidence, impact and preventative strategies for non- access site bleeding in the PCI patient Martial Hamon. MD. FESC University Hospital. Caen. France.
BLEEDING AND ACUTE CORONARY SYNDROMES Cardiac Catherization Conference Syed Raza MD Cardiology Fellow VCU Medical Center 06/02/2011.
ICE Hellenic PCI Registry Organization - Structure - Directions - Initial Recordings Georgios I. Papaioannou, MD,
Sunil V. Rao MD The Duke Clinical Research Institute The Durham VA Medical Center Duke University Medical Center Transradial PCI in Octogenarians: Caveats,
Welcome Ask The Experts March 24-27, 2007 New Orleans, LA.
CPORT- E Trial Randomized trial comparing outcomes of non-primary PCI at hospitals with and without on-site cardiac surgery.
Prasugrel vs. Clopidogrel for Acute Coronary Syndromes Patients Managed without Revascularization — the TRILOGY ACS trial On behalf of the TRILOGY ACS.
Use of Arteriotomy Closure Devices and the Risk of Vascular Complications: An Analysis of 227,879 Patients in the NCDR Sameer K. Mehta MD, Andrew D. Frutkin.
Athens Cardiology Update CADILLAC Study Blood Transfusion after Myocardial Infarction: Friend, Foe or double-edged Sword? Georgios I. Papaioannou,
Michael A. Nelson, MD 1 Michele D. Voeltz, MD 1 Frederick Feit, MD 2 A. Michael Lincoff, MD 3 Steven V. Manoukian, MD 1 1 Emory University School of Medicine.
Vorapaxar for Secondary Prevention in Patients with Prior Myocardial Infarction Benjamin M. Scirica, MD, MPH On behalf of the TRA 2°P-TIMI 50 Steering.
A Novel Score to Estimate the Risk of Pneumonia After Cardiac Surgery
Baseline Characteristics Current or Former Smoker Diabetic Hypertension 25.7 Prior MI Prior Heart Failure.
Presenter Disclosure Information DISCLOSURE INFORMATION: The following relationships exist related to this presentation Stock options None; Consults for.
Safety and Efficacy of Switching from Either UFH or Enoxaparin Plus a GP IIb/IIIa Inhibitor to Bivalirudin Monotherapy in Patients with Non-ST Elevation.
Determination of the RAdial versus GrOiN coronary angioplasty The Result of DRAGON Trial Shigeru Saito, MD Department of Cardiology and Catheterization.
Ramin Ebrahimi, MD University of California Los Angeles/ Greater Los Angeles VA Medical Center Implications of Preoperative Thienopyridine Use Prior to.
Clinical Trial Results. org Characteristics, Management, and Outcomes of 5,557 Patients Age ≥90 Years With Acute Coronary Syndromes: Results From the CRUSADE.
Major Bleeding is Associated with Increased 30-Day Mortality and Ischemic Complications in Patients with Non-ST Elevation Acute Coronary Syndromes Undergoing.
Nick Alp Milton Keynes Hospital NHS FT Oxford Radcliffe NHS Trust Bleeding risks in the major trials – It does matter.
Gregg W. Stone MD for the ACUITY Investigators Gregg W. Stone MD for the ACUITY Investigators A Prospective, Randomized Trial of Bivalirudin in Acute Coronary.
Major Bleeding is Associated with Increased One-Year Mortality and Ischemic Events in Patients with Acute Coronary Syndromes Undergoing Percutaneous Coronary.
Allen Jeremias, Neal Kleiman, Deborah Nassif, Wen-Hua Hsieh, Michael Pencina, Kelly Maresh, Manish Parikh, Donald Cutlip, Ron Waksman, Steven Goldberg,
Eptifibatide plus Heparin Increases the Risk of Major and Minor Hemorrhagic Complications Compared to Bivalirudin in Patients with Normal Renal Function.
Gender Differences in Long-Term Outcomes Following PCI of Patients with Non-ST Elevation ACS: Results from the ACUITY Trial Alexandra J. Lansky on behalf.
The Effect of Cangrelor and Access Site on Ischemic and Bleeding Events – Insights from CHAMPION PHOENIX J. Antonio Gutierrez, MD, MHS, Robert A. Harrington,
Antiplatelet Therapy Use after Discharge among Acute Myocardial Infarction Patients with In-hospital Bleeding Tracy Y. Wang, MD, MHS, Lan Xiao, PhD, Karen.
Gregg W. Stone MD for the ACUITY Investigators A Prospective, Randomized Trial of Bivalirudin in Acute Coronary Syndromes Final One-Year Results from the.
Duration Safety and Efficacy of Bivalirudin in patients undergoing PCI: The impact of duration of infusion in ACUITY trial Dr. David Cox Lehigh Valley.
Ten Year Outcome of Coronary Artery Bypass Graft Surgery Versus Medical Therapy in Patients with Ischemic Cardiomyopathy Results of the Surgical Treatment.
Pros and Cons of Radial Access
Major Bleeding is Associated with Increased Short-Term Mortality and Ischemic Complications in Non-ST Elevation Acute Coronary Syndromes: The ACUITY Trial.
Women, Bleeding, and Coronary Intervention
Why Radial Access Should be the Default for Women undergoing PCI?
Antiplatelet Therapy For STEMI: The Case for Cangrelor
Transfusion is Associated with Increased 30-Day Mortality and Ischemic Complications in Non-ST Elevation Acute Coronary Syndromes: The ACUITY Trial Steven.
POISE-2 PeriOperative ISchemic Evaluation-2 Trial
How to Minimize Bleeding in STEMI Patients Outline: -Know about bleeding -Think about consequences of bleeding -Identify bleeding risk factors -Maximize.
Impact of clopidogrel loading dose on the safety and effectiveness of bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction:
Antiplatelet Therapy Use after Discharge among Acute Myocardial Infarction Patients with In-hospital Bleeding Tracy Y. Wang, MD, MHS, Lan Xiao, PhD, Karen.
The Synergy between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery: The SYNTAX Study One Year Results of the PCI and CABG Registries.
Hellenic PCI Registry Organization - Structure - Directions - Initial Recordings Georgios I. Papaioannou, MD, MPH, FACC,
Incidence and management of restenosis after treatment of unprotected left main disease with drug-eluting stents: 70 restenotic cases from a cohort of.
Implications of Preoperative Thienopyridine Use
No Financial Disclosure or Conflict of Interest
The Synergy between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery: The SYNTAX Study One Year Results of the PCI and CABG Registries.
Baseline Characteristics
Atlantic Cardiovascular Patient Outcomes Research Team
Adjusted. ORs for outcomes by maintenance P2Y12 treatment
Presentation transcript:

Bleeding in Patients Undergoing Percutaneous Coronary Interventions: A Risk Model From 302,152 Patients in the NCDR. Sameer K. Mehta MD, Andrew D. Frutkin MD, Sunil V. Rao MD, Fang–Shu Ou MS, Eric D. Peterson MD, MPH, John A. Spertus MD, MPH, Steven P. Marso MD, on behalf of the NCDR The Mid America Heart Institute and Duke Clinical Research Institute. American Heart Association Scientific Sessions – November 5, 2007

Presenter Disclosure Information Sameer K. Mehta MD et al. Bleeding in Patients Undergoing Percutaneous Coronary Interventions: A Predictive Model From 302,152 Patients in the NCDR. No authors report any disclosures or conflicts of interest.

Bleeding and PCI The incidence of major bleeding in patients undergoing PCI is as high as 5%. Bleeding events have been associated with an increased incidence of adverse outcomes, including death, MI, and stroke. A tool that helps physicians assess the risk of bleeding in PCI patients may allow physicians to individualize antithrombotic and antiplatelet therapy while mitigating the risk of bleeding. Goodman et al. Circulation Eikelboom et al. Circulation Rao et al. American Journal of Cardiology 2005.

Aims To determine the risk factors of bleeding in a large, contemporary, real-world cohort of patients undergoing PCI. To develop a risk model for bleeding. To test the validity of this risk model in clinically important subgroups.

Methods Version 3.04 of NCDR Cath-PCI Registry Contains data from PCI procedures performed from Jan. 1, 2004 to March 31, 2006 at over 600 U.S. hospitals. Exclusions: -Non-index PCI -Patients who died same day as PCI -Patients with missing bleeding data -Centers that did not report any bleeding events

Methods (2) Final study population: –302,152 patients –302,152 PCI procedures –440 U.S. hospitals Determined predictors of bleeding with generalized estimating equation models. –Models adjusted for age, sex, weight, GFR, PCI status, presence of ACS, cardiogenic shock, intra-aortic balloon pump treatment, history of MI, diabetes, cerebrovascular disease, peripheral vascular disease, hypertension, COPD, prior PCI, NYHA class, prior valve surgery, Caucasian, prior CHF, smoker, family history of CAD, EF, dyslipidemia, prior CABG, and CHF.

Methods (3) Risk model training set. –241,512 patients (80% of total) Risk model validation set –60,640 patients (20% of total) Variable selection via backward selection and clinical judgment Goodness of fit determined by calibration plot Discrimination assessed by c-statistic Risk model tested in various clinically meaningful subgroups

NCDR Bleeding Definitions Primary Endpoint: Bleeding from any source Percutaneous entry site: –during hospitalization; –transfusion and/or cause a drop in hemoglobin >3.0 g/dl; –hematoma >10cm for femoral access, >2cm for radial access, or >5cm for brachial access. Retroperitoneal: –transfusion and/or cause a drop in hemoglobin >3.0 g/dl.

NCDR Bleeding Definitions (2) GI: –transfusion and/or cause a drop in hemoglobin >3.0 g/dl. GU: –transfusion and/or cause a drop in hemoglobin >3.0 g/dl. Other/Unknown: –During hospitalization –transfusion and/or cause a drop in hemoglobin >3.0 g/dl.

Select Baseline Characteristics Age (years, median)64 Female (%)34 Caucasian (%)87 Weight <50 kg (%)1.5 GFR <30 (%)10 Hypertension (%)25 ACS (%)66 Cardiogenic Shock (%)2.0 IABP (%)2.2 2b/3a Use (%)48 Direct Thrombin Inhibitor (%)32

Results Incidence of Bleeding in Training Set 2.5%

Risk Factors for Bleeding- Adjusted Analysis VariableOR95% CI  Square Female Age (per 10 yrs) GFR (per 10 ml/min decrease) Prior PCI Cardiogenic Shock Emergent/Salvage PCI Urgent PCI COPD All p values <0.001

Risk Factors for Bleeding- Adjusted Analysis VariableOR95% CI  Square NYHA Class 3 NYHA Class Non-STEMI/ Unstable Angina STEMI Prior Valve Surgery CVD Intra-aortic balloon pump PVD HTN Weight (per 5 kg decrease)

Overall Model N= 60,640 C Statistic =0.73 Predicted Bleeding (%) Observed Bleeding (%)

Subgroup Analyses N= 9,130 C Statistic =0.70 N= 30,872 C Statistic =0.72 Predicted Bleeding (%) Observed Bleeding (%)

Elective PCI Patients N= 29,733 C Statistic =0.67 Predicted Bleeding (%) Observed Bleeding (%)

Antithrombotic Therapy N=24,969 C Statistic =0.73 N= 22,666 C Statistic =0.72 Predicted Bleeding (%) Observed Bleeding (%) Unfractionated Heparin Unfractionated Heparin plus IIb/IIIa

Antithrombotic Therapy N= 19,316 C Statistic =0.73 N= 10,108 C Statistic =0.68 Predicted Bleeding (%) Observed Bleeding (%) Low Molecular Weight Heparin Direct Thrombin Inhibitors

Conclusions Identified risk factors for bleeding in PCI patients Developed a risk model that predicted the risk of bleeding in patients undergoing PCI Model performed well in various clinically important subgroups

Limitations Bleeding definitions differ between NCDR and TIMI/ GUSTO Low reported incidence of bleeding events

Future Directions Risk Score for Bleeding. Implementation of predictive model/ risk score into randomized studies of patients undergoing PCI.